Adamantane 281-23
  • Adamantane 281-23Adamantane 281-23

Adamantane 281-23

Adamantane 281-23-2 a nobis emere gratissimum est. Amantadine, quae amantadine vel tricyclodecylamine nota est, primum medicamento antivirali usus est et postea inventus est effectus morborum anti-Parkinson. 1. Morbus anti-parkinsonis: Post amantadinem cerebrum ingreditur, liber chemicus potest emissionem dopaminis transmissorum a dopaminergicis neuronibus promovere et inhibere restitutionem dopaminis. Praeterea, chemical book dopamine receptores directe excitare potest, cuius efficacia non est sicut bonum

Mitte Inquisitionem

depictio producti

Crede Chemical Adamantane est 281-23-2 fabricatores et praebitores in Sinis qui possunt Lupum Adamantanum 281-23-2. Shandong Credite


Adamantane 281-23-2 Specification

Product Name

Adamantanum

Formulae

C10H16

M. Pondus

136.23

CAS NO.

281-23-2

quantitas

500KG


Items

Specification

Proventus

Aspectus

Crystallum album pulveris

Conforms

Assay

≥ 99%

Conforms

Liquescens punctum

209-212 °C (subl.)

Conforms

Densitas

1,07 g/cm3

Conforms

CONCLUSIO

Effectus conformis vexillum


Adamantane 281-23-2 Chemical Properties

Synonym: TRICYCLO[3.3.1.1]DECANE;TRICYCLO[3.3.1.13,7] DECANI; ;decahydro-3,5,1,7-[1,2,3,4]butanetetraylnaphthalene;Tricyclo(3,3,1,1,3,7)-decane


CAS;

Formulae hypotheticae:

Pondus hypotheticum:

EINECS: 206-001-4

Ferveret:

Densitas:

Repono conditiones:

Index refractivus:

Vita fasciae: 2 years


Adamantane 281-23-2 Chemical

Adamantane CAS

Adamantane CAS



Hot Tags: Adamantane 281-23-2, Manufacturers, Suppliers, Lupum, Factory, In Stock, Factus in Sinis, China, Cheap, Discount, Qualitas, API, Investigatio et Progressio, Consuetudo Synthesis

Product Tag

Related Categoria

Mitte Inquisitionem

Libenter placet, ut inquisitionem tuam in forma infra exhibeas. Respondebimus tibi in 24 horis.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept